| __timestamp | Agios Pharmaceuticals, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 14400000 |
| Thursday, January 1, 2015 | 141827000 | 33800000 |
| Friday, January 1, 2016 | 220163000 | 35900000 |
| Sunday, January 1, 2017 | 292681000 | 1254000 |
| Monday, January 1, 2018 | 1397000 | 4889000 |
| Tuesday, January 1, 2019 | 1317000 | 7400000 |
| Wednesday, January 1, 2020 | 2805000 | 10100000 |
| Friday, January 1, 2021 | 18777000 | 14300000 |
| Saturday, January 1, 2022 | 1704000 | 23200000 |
| Sunday, January 1, 2023 | 9504000 | 39700000 |
| Monday, January 1, 2024 | 4165000 | 34000000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, cost efficiency is paramount. Neurocrine Biosciences, Inc. and Agios Pharmaceuticals, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Agios Pharmaceuticals started with a high cost of revenue, peaking in 2017, but saw a significant reduction of over 90% by 2022. In contrast, Neurocrine Biosciences maintained a more stable and efficient cost structure, with a notable increase in 2023, reaching nearly 40 million. This divergence highlights Neurocrine's consistent approach to managing costs, while Agios has made strides in improving its efficiency over the years. These trends underscore the importance of strategic financial management in sustaining growth and competitiveness in the biotech sector.
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Jazz Pharmaceuticals plc vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Agios Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.